Comparative Pharmacology
Head-to-head clinical analysis: GADAVIST versus GADOBUTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GADAVIST versus GADOBUTROL.
GADAVIST vs GADOBUTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gadovist (gadobutrol) is a macrocyclic gadolinium-based contrast agent (GBCA) that enhances MRI signal intensity by shortening T1 relaxation time in tissues with altered vascularity or blood-brain barrier integrity.
Gadobutrol is a gadolinium-based contrast agent (GBCA) that shortens T1 relaxation time in magnetic resonance imaging (MRI), enhancing signal intensity in tissues where it distributes. It is a paramagnetic agent that increases the relaxation rate of water protons in the vicinity of the gadolinium ion.
0.1 mmol/kg (0.2 mL/kg) IV bolus; maximum dose 0.3 mmol/kg per imaging session.
0.1 mmol/kg (0.1 mL/kg) intravenous bolus; maximum dose 0.1 mmol/kg per contrast study. Repeat dosing up to 0.2 mmol/kg total during a single session may be considered on clinical judgment.
None Documented
None Documented
Plasma terminal elimination half-life is approximately 1.5 hours in patients with normal renal function (GFR >60 mL/min/1.73m²). In renal impairment (GFR <30 mL/min/1.73m²), half-life extends to 10-15 hours; in end-stage renal disease, half-life may exceed 30 hours, necessitating adjustment of imaging timing.
Terminal elimination half-life: 1.24-2.23 hours (healthy); may be prolonged in renal impairment (up to 9.6 hours in severe impairment).
Primarily renal; approximately 95% of administered dose excreted unchanged in urine within 72 hours, with 85% eliminated within 6 hours. Less than 1% excreted in feces.
Primarily renal (90-95% unchanged within 24 hours); less than 0.3% fecal.
Category C
Category A/B
Contrast Agent
Contrast Agent